Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesNeurology/NeurosurgeryAetna Natalizumab Coverage & Prior Auth Update | O…
    Ask Trek AI about this page
    CurrentAetnaPolicy 0751

    Natalizumab

    Customize your policy alerts

    Sign up for Aetna Policy 0751 alerts

    Get alerted when Policy 0751 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Clinical coverage and utilization management criteria for natalizumab (Tysabri and biosimilar Tyruko) for Crohn's disease and relapsing forms of multiple sclerosis, including precertification and site-of-care notes, for Aetna commercial medical plans.

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Policy Summary
    PayerAetna
    PolicyNatalizumab
    Policy CodePolicy 0751
    Change TypeNo material change
    Effective Date04/11/2008
    Last ReviewFeb 20, 2024
    Next Review Date08/22/2024
    Key ActionObtain precertification and submit documentation including diagnosis, prior therapies, and anti‑JCV antibody test results when requesting natalizumab.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    Precertification requiredPrior authorization requirement
    300 mg IV q4wStandard dosing
    Anti‑JCV antibodyTesting recommended
    PMLSerious adverse event
    6%Persistent antibodies (AFFIRM)
    02/20/2024Last review

    Coverage Criteria for Natalizumab

    FDA‑indicated and recommended use — Covered when ALL of the following are met:

    Covered when ALL of the following are met:

    ALL of the following

    • Indication: The member has a diagnosis of moderately to severely active Crohn's disease (CD) with evidence of inflammation, OR a relapsing form of multiple sclerosis (including clinically isolated syndrome, relapsing-remitting MS, or active secondary progressive MS).
    • Prior treatment failure or intolerance: For Crohn's disease, the adult member has had an inadequate response to, or is unable to tolerate, conventional CD therapies and inhibitors of tumor necrosis factor alpha (TNF-α) (e.g., infliximab, adalimumab).
    • Prescriber specialty: The medication is prescribed by or in consultation with an appropriate specialist (gastroenterologist for Crohn's disease; neurologist for multiple sclerosis or clinically isolated syndrome).
    • Enrollment in restricted distribution program: The member (and prescriber/infusion provider) are enrolled in and compliant with the applicable TOUCH/CD-TOUCH prescribing program and monitoring requirements as required by the FDA labeling.
    • Risk assessment and testing: The member has been evaluated for risk of progressive multifocal leukoencephalopathy (PML), including baseline MRI as clinically indicated and anti‑JC virus (JCV) antibody testing performed prior to initiation and documented in the medical record.
    • Concomitant medications: Natalizumab is to be used as monotherapy and not in combination with other disease‑modifying MS agents, immunosuppressants, or TNF inhibitors (concurrent use with agents such as azathioprine, 6‑mercaptopurine, methotrexate, infliximab, adalimumab is not allowed).

      Per FDA labeling and product safety guidance.

    • For Crohn's disease only: Documentation of clinical response or remission on therapy and plan for steroid tapering if corticosteroids are being used; if no improvement at approximately 3 months, therapy should be discontinued per CD‑TOUCH guidance.
    • Safety monitoring and documentation: Provider documents monitoring plan for signs/symptoms of PML, infusion‑related adverse events, and antibody testing if a suboptimal clinical response or persistent infusion reactions occur (anti‑natalizumab antibody testing recommended when suspected).

    Billing and Coding

    Covered CPT Codes (testing)CPTCovered
    86711Antibody; JC (John Cunningham) virus.
    CPT Codes (PCR testing) - not covered for pre-initiation CSF PCRCPTNot Covered
    87798Infectious agent detection by nucleic acid (DNA or RNA), not otherwise specified; amplified probe technique, each organism.
    87801Infectious agent detection by nucleic acid (DNA or RNA), multiple organisms; amplified probe technique.
    Other related CPT CodesCPT
    86790Antibody; virus, not elsewhere specified [anti-JCV antibody testing with ELISA].
    Infusion CPT CodesCPTCovered
    96365Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour.
    96366Intravenous infusion; each additional hour.
    96367Intravenous infusion, concurrent infusion (if listed).
    96368Intravenous infusion, for therapy, prophylaxis, or diagnosis; therapeutic infusion requiring prolonged infusion time.
    96379Unlisted therapeutic, prophylactic, or diagnostic intravenous or intra-arterial injection or infusion.
    Covered HCPCS CodesHCPCSCovered
    J2323Injection, natalizumab, 1 mg.
    Other HCPCS Codes related to CPBHCPCS
    J0135Injection, adalimumab, 20 mg.
    J0202Injection, alemtuzumab, 1 mg.
    J1595Injection, glatiramer acetate, 20 mg.
    J1745Injection, infliximab, 10 mg.
    J1826Injection, interferon beta-1a, 30 mcg.
    J1830Injection, interferon beta -1b, 0.25 mg.
    J2350Injection, ocrelizumab, 1 mg.
    J3245Injection, tildrakizumab, 1 mg.
    J7500Azathioprine, oral, 50 mg.
    J7501Azathioprine, parenteral, 100 mg.
    1–10 of 13
    1/2
    Covered ICD-10 CodesICD-10Covered
    G35Multiple sclerosis [relapsing, not chronic progressive].
    G37.8Other specified demyelinating diseases of central nervous system [clinically isolated syndrome].
    K50.00Crohn's disease [Adults only].
    K50.919Crohn's disease, unspecified behavior/location (range shown in policy K50.00 - K50.919).
    Not Covered ICD-10 Codes / IndicationsICD-10Not Covered
    C94.80Malignant neoplasm of lymphoid, hematopoietic and related tissue (listed among not covered).
    G04.81Other encephalitis and encephalomyelitis [Rasmussen encephalitis].
    G36.0Neuromyelitis optica [Devic].
    G61.81Chronic inflammatory demyelinating polyneuritis.
    I63.00Cerebral infarction [acute ischemic stroke].
    K51.00Ulcerative colitis.
    Retest interval for anti‑JCV antibody when negative
    Retest intervalAnti‑JCV antibody negative tests should be retested every 6 months.
    PurposeDetect seroconversion because negative status can change and a new JCV infection or false negative is possible.
    Assay requirementUse an analytically and clinically validated immunoassay to determine anti‑JCV antibody status.

    Provider Actions and Requirements

    Prior Authorization

    Precertification required for natalizumab and associated codes

    Precertification (prior authorization) is required for natalizumab (Tysabri, Tyruko) — providers must obtain precertification before administration. Failure to obtain required precertification may result in denial or delay of coverage.

    • Precertification phone: (866) 752-7021; fax: (888) 267-3277
    • Precertification forms: Specialty Pharmacy Precertification link (Aetna)
    • Applies to natalizumab products (J2323) and related infusion billing codes (96365–96368, 96379)
    Prior Authorization

    Prior authorization for indicated use

    Prior authorization is required to document FDA‑indicated use and medical necessity. Prescribers must demonstrate the appropriate indication (relapsing forms of MS, clinically isolated syndrome, or moderately to severely active Crohn’s disease per policy) and that recommended prior therapies or conditions have been met.

    • MS: relapsing forms (including relapsing‑remitting and active secondary progressive) or CIS

    Background and Context

    Natalizumab is a humanized monoclonal antibody that targets alpha‑4 integrin and is indicated as monotherapy for relapsing forms of multiple sclerosis and for induction and maintenance of response in selected adults with moderate‑to‑severe Crohn's disease. The drug carries a boxed warning for progressive multifocal leukoencephalopathy (PML); known risk factors include anti‑JCV antibody positivity, prior immunosuppressant use, and longer duration of therapy.

    Definitions and Key Terms

    Progressive multifocal leukoencephalopathy (PML)
    DefinitionProgressive multifocal leukoencephalopathy (PML) is an opportunistic viral infection of the brain that usually leads to death or severe disability.
    Risk factorsRisk increased with anti‑JCV antibody positivity, prior immunosuppressant use, and longer duration of natalizumab therapy (especially beyond 2 years).
    Risk managementNatalizumab products are available only through a restricted distribution program (TOUCH) because of PML risk.
    Anti‑JCV antibody status
    Test descriptionAnti‑JCV antibody testing is performed with an analytically and clinically validated immunoassay to determine exposure to JC virus.
    InterpretationA positive anti‑JCV antibody at any time classifies the patient as antibody positive for risk assessment regardless of prior or subsequent results.

    Policy Revision History

    2024-02-20reviewLatest

    Policy last reviewed (document status: CURRENT).

    2008-04-11effective_date

    Policy became effective on this date (original effective date recorded).

    Policy Summary
    PayerAetna
    PolicyNatalizumab
    Policy CodePolicy 0751
    Change TypeNo material change
    Effective Date04/11/2008
    Last ReviewFeb 20, 2024
    Next Review Date08/22/2024
    Key ActionObtain precertification and submit documentation including diagnosis, prior therapies, and anti‑JCV antibody test results when requesting natalizumab.
    SourceLink
    On This Page
    Coverage Criteria for NatalizumabBilling and CodingProvider Actions and RequirementsBackground and ContextDefinitions and Key TermsPolicy Revision History
  1. CD: adults with moderate‑to‑severe Crohn’s disease who have had inadequate response to, or intolerance of, conventional therapies and TNF‑α inhibitors
  2. Codes: J2323 (natalizumab), relevant CPT/HCPCS infusion codes
  3. Prior Authorization

    Prior authorization for NTZ vs alternatives

    When requesting natalizumab, providers should justify choice of natalizumab versus alternative therapies (e.g., fingolimod) using available comparative‑effectiveness evidence and individualized risk assessment; observational and indirect comparisons have limitations and may require clinical justification in the record.

    • Comparative evidence: observational studies suggest NTZ may reduce relapses vs fingolimod but head‑to‑head RCTs are lacking — document rationale and prior therapy history
    • Consider alternative DMTs and balance benefits vs PML risk (anti‑JCV antibody status, prior immunosuppressant/TNF exposure)
    Denial Risk

    Experimental/Investigational exclusions

    Use of natalizumab concurrently with other disease‑modifying MS agents, immunosuppressants, or TNF inhibitors is considered experimental and investigational and is not supported by this policy.

    • Examples: concurrent use with adalimumab, infliximab, azathioprine, 6‑mercaptopurine, methotrexate
    • Policy: concomitant use with other DMTs or TNF inhibitors = experimental/investigational
    Documentation Required

    Required documentation, testing, and TOUCH/CD‑TOUCH enrollment

    Providers must submit required clinical documentation and testing results with authorization requests, including diagnosis, prior therapies tried and responses, and anti‑JCV antibody test results when available. Failure to enroll or comply with restricted distribution/safety monitoring programs (TOUCH or CD‑TOUCH) may affect authorization.

    • Documentation: diagnosis, prior biologics/immunosuppressants tried, objective response measures for CD (weight, abdominal pain, diarrhea, hematocrit) or MS disease activity
    • Testing: anti‑JCV antibody testing (86790) — retest every 6 months if negative; MRI prior to initiation for MS
    • Program enrollment: documentation of TOUCH (MS) or CD‑TOUCH enrollment and scheduled evaluations at 3 and 6 months, then every 6 months thereafter
    Documentation Required

    EDSS documentation

    EDSS scoring may be required to document disease severity and disability for MS members; ensure EDSS is completed by a neurologist and included in the medical record when relevant to the authorization.

    • Include EDSS score and date of exam (scale 0–10 in 0.5 increments)
    • Document clinician performing EDSS (neurologist) and how score supports medical necessity
    Note

    Comparative effectiveness evidence limitations

    Comparative‑effectiveness and observational evidence have limitations (no head‑to‑head RCTs versus some alternatives); reviewers may request additional clinical rationale and prior treatment history when NTZ is selected over other disease‑modifying therapies.

    • Observational studies and indirect comparisons suggest potential superiority of NTZ for relapse reduction but are subject to confounding
    • Operational note: provide objective prior therapy failures/intolerance and risk stratification (anti‑JCV status) to support NTZ use
    Denial Risk

    Off‑label epilepsy indication unsupported

    Natalizumab has been studied as adjunctive therapy for drug‑resistant epilepsy and did not meet the pre‑defined threshold for effectiveness; this off‑label indication is unsupported by current evidence and is considered experimental.

    • Phase II trial (French et al, 2021) did not demonstrate significant seizure reduction versus placebo
    • Policy: adjunctive therapy for drug‑resistant epilepsy = experimental/investigational
    Note

    No step therapy requirements or sequencing

    This policy section does not list specific step‑therapy sequencing rules; no step therapy requirements are included for natalizumab in the provided policy excerpts.

    • No step therapy rules present in policy excerpts
    • Site‑of‑care UM policy still applies for infusion location
    Note

    Administrative notices and links

    Administrative notices: policy history, review dates, links to additional resources, and disclaimers are included in the document — consult the policy history and clinical policy bulletin notes for updates.

    • Effective date: 2008‑04‑11; Last review: 02/20/2024; Next review: 08/22/2024
    • Links: Clinical Policy Bulletin Notes, Definitions, Review History
    • Disclaimer: CPB is not a contract and may be updated
    Negative result actionPatients with a negative anti‑JCV antibody test should be retested every 6 months because status can change or false negatives can occur.
    Clinically Isolated Syndrome (CIS)
    DefinitionClinically Isolated Syndrome (CIS) is a first episode of neurologic symptoms caused by inflammation and demyelination lasting at least 24 hours that is characteristic of MS but does not yet meet diagnostic criteria for MS.
    Prognostic noteWhen CIS is accompanied by MS‑like lesions on brain MRI, there is a higher likelihood of progression to relapsing‑remitting MS.
    Progressive Multifocal Leukoencephalopathy (PML)
    DescriptionProgressive multifocal leukoencephalopathy (PML) is a rare, serious opportunistic CNS infection associated with natalizumab use.
    Estimated trial‑based riskBased on clinical trial data, PML risk has been estimated at approximately 1 per 1,000 patients treated for an average of 17.9 months.
    Clinical implicationPML risk necessitates enrollment in risk‑management programs and consideration of benefit versus risk when initiating or continuing natalizumab.
    Expanded Disability Status Scale (EDSS)
    ScaleEDSS ranges from 0 to 10 in 0.5 increments to quantify disability in multiple sclerosis.
    Scoring basisScoring is based on a neurologic examination performed by a neurologist.
    UseUsed to monitor changes in disability level over time and document disease severity for clinical decision‑making.
    Clinical Policy Bulletin Notes / Definitions
    Supplemental definitionsLinks to Aetna's Clinical Policy Bulletin Notes and supplemental definitions are provided in the policy for additional reference.
    Content noteFull definitions referenced in those supplemental materials are not present within the supplied policy excerpts.
    Where to findRefer to the Clinical Policy Bulletin Notes and Definitions links in the policy history/appendix for complete entries.